Key result
EPLURIBUS evaluates the diagnostic performance of whole-heart CCT versus CMR in new-onset LV dysfunction.
Why the study?
While CMR is the standard for detecting myocardial fibrosis, CCT is emerging as a promising alternative, prompting evaluation of its feasibility and diagnostic accuracy for comprehensive cardiac evaluation.
Does cardiac computed tomography provide comparable diagnostic accuracy to cardiac magnetic resonance for evaluating delayed enhancement and ventricular function in patients with newly diagnosed LV dysfunction?
Observational (n=100)
Does cardiac computed tomography provide comparable diagnostic accuracy to cardiac magnetic resonance for evaluating delayed enhancement and ventricular function in patients with newly diagnosed LV dysfunction?
The EPLURIBUS study will evaluate the feasibility and diagnostic accuracy of whole-heart coverage CCT compared to CMR for comprehensive functional and anatomical evaluation in patients with new-onset LV dysfunction.
BACKGROUND: Cardiac magnetic resonance (CMR) is the standard of reference for myocardial fibrosis detection by late gadolinium enhancement. Cardiac computed tomography (CCT) is emerging as a promising alternative. The Evidence for a comPrehensive evaLUation of left ventRicle dysfnctIon By a whole-heart coverage cardiac compUted tomography Scanner study will assess the feasibility and diagnostic accuracy of a comprehensive functional and anatomical cardiac evaluation with CCT as compared with CMR and invasive coronary angiography as standard of reference. METHODS: Consecutive patients with a newly diagnosed left ventricle (LV) dysfunction (left ventricular ejection fraction <50%) and a clinical indication to CMR will be screened. Exclusion criteria will be contraindications to contrast agents and impaired renal function. CCT will be performed per protocol within 10 days from CMR. A total of 100 patients will be enrolled within 24 months. We will evaluate with CCT volume and ejection fraction of the LV and right ventricle, presence, extent and pattern of delayed enhancement and cardiac venous system. Moreover, presence and degree of coronary stenoses will be evaluated among patients undergoing invasive coronary angiography in the 6 months following CCT. RESULTS: The primary study endpoints will be: first, to assess the diagnostic performance of CCT vs. CMR to detect the delayed enhancement in a territory-based and patient-based analysis; second, to assess the agreement between CCT and CMR in the discrimination between ischemic vs. nonischemic delayed enhancement patters in a territory-based analysis; third, to assess the correlation between CCT and CMR for LV and right ventricle end-diastolic and end-systolic volumes and ejection fraction measurements. CONCLUSION: The Evidence for a comPrehensive evaLUation of left ventRicle dysfnctIon By a whole-heart coverage cardiac compUted tomography Scanner study will assess the diagnostic performance of CCT using the latest scanner generation for a comprehensive evaluation of patients with new-onset LV dysfunction.
No takes yet. Share an insight, caveat, or question.
Andreini et al. (2020) conducted an observational in Newly diagnosed left ventricle dysfunction (n=100). Cardiac computed tomography (CCT) vs. Cardiac magnetic resonance (CMR) and invasive coronary angiography was evaluated on Diagnostic performance of CCT vs. CMR to detect delayed enhancement, agreement in ischemic vs. nonischemic patterns, and correlation for ventricular volumes and ejection fraction. The EPLURIBUS study is designed to assess the diagnostic performance of whole-heart coverage cardiac computed tomography compared with cardiac magnetic resonance in 100 patients with new-onset LV dysfunction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: